All In Biotech

Drug Trial Radar · NCT04064359

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 25, 2019

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Oxford BioTherapeutics LtdIndustry
Sponsor type
Industry
First posted
Aug 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.

Conditions

  • Solid Tumor

Interventions

  • OBT076, a CD205-directed antibody-drug conjugateDrug

    Intravenous (IV) infusion of OBT076 every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) as assessed by NCI CTCAE (Version 5)Time frame: 1 year
  2. Percentage of subjects with dose-limiting toxicities (DLTs) as assessed by NCI CTCAE (Version 5)Time frame: 1 year

Locations

27 sites in 5 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona

  • Cedars-Sinai

    Los Angeles, California

  • UCLA

    Santa Monica, California

  • Moffitt Cancer Center

    Tampa, Florida

  • The State University of Iowa

    Iowa City, Iowa

  • St. Elizabeth Healthcare

    Edgewood, Kentucky

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Quantum Santa Fe

    Santa Fe, New Mexico

  • Columbia University Medical Center

    New York, New York

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Institut Jules Bordet

    Brussels, Belgium

  • AZ Groeninge

    Kortrijk, Belgium

  • Institut Paoli Calmettes

    Marseille, France

  • GHP Saint-Joseph

    Paris, France

  • Hopital Saint Antoine

    Paris, France

  • Hopital Saint Louis

    Paris, France

  • Centre Eugène Marquis

    Rennes, France

  • ICANS - Institut de cancérologie Strasbourg

    Strasbourg, France

  • Institut Gustave Roussy - IGR

    Villejuif, France

  • Metropolitan Hospital

    Athens, Greece

  • Sotiria General Hospital

    Athens, Greece

  • University General Hospital of Heraklion

    Heraklion, Greece

  • EuroMedica

    Thessaloniki, Greece

  • University General Hospital Attikon

    Chaïdári, Athens, Greece

  • START Barcelona HM Nou Delfos

    Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • University Hospital Marqués de Valdecilla

    Santander, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.